Strategic Partnerships Pharmathen has a strong global network (90+ countries) and collaborates with major pharma players, presenting opportunities for co-development, licensing, or distribution partnerships to accelerate LAI, sustained-release, and ophthalmic product access.

LAI and LATT Focus The company emphasizes long acting injectables and advanced drug delivery platforms, signaling potential for collaboration on development, manufacturing, or optimization of LAI pipelines for psychiatry, chronic diseases, and other segments needing extended release therapies.

Vertical Integration With US FDA and EU-approved facilities and a diversified portfolio of over 100 products, Pharmathen can support end-to-end needs from formulation to manufacturing, offering scalable manufacturing partnerships for complex therapies and rapid market entry.

Expansion Momentum Recent acquisitions and facility expansions in Greece and Southern Europe, plus a push to grow in the US and Europe, create opportunities for sales teams to propose capacity, technology licensing, and regional manufacturing arrangements.

R&D and Compliance Strong emphasis on research, female-dominated R&D teams, and adherence to ISO 9001 and cybersecurity standards indicate readiness for regulated development partnerships, quality-focused collaborations, and joint innovation programs.